News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,529 Results
Type
Article (8069)
Company Profile (140)
Press Release (476319)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166803)
Career Advice (305)
Deals (25746)
Drug Delivery (7)
Drug Development (52912)
Employer Resources (14)
FDA (9765)
Job Trends (8580)
News (238301)
Policy (17922)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33165)
ALS (104)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (263)
Approvals (10373)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6961)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (508)
Cancer (3640)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (477)
Cervical cancer (34)
Clinical research (47873)
Collaboration (1240)
Commercialization (3)
Compensation (1449)
Complete response letters (34)
COVID-19 (760)
CRISPR (63)
C-suite (738)
Cystic fibrosis (85)
Data (5625)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4178)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73685)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87592)
Executive appointments (698)
FDA (12373)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (910)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (941)
Grass and pollen (2)
Guidances (281)
Healthcare (9320)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (57)
Indications (156)
Infectious disease (948)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1970)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (511)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14381)
Metabolic disorders (705)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1818)
NextGen: Class of 2026 (3152)
Non-profit (841)
Obesity (223)
Opinion (11)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (196)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41222)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15474)
Phase 2 (21386)
Phase 3 (14406)
Pipeline (7239)
Policy (18)
Postmarket research (1570)
Preclinical (6538)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3022)
Recruiting (6)
Regulatory (14792)
Reports (20)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (4)
Supply chain (50)
Vaccines (320)
Venture capital (17)
Weight loss (74)
Women's health (78)
Date
Today (96)
Last 7 days (457)
Last 30 days (1669)
Last 365 days (19140)
2026 (12080)
2025 (19258)
2024 (23000)
2023 (26545)
2022 (34595)
2021 (37189)
2020 (33471)
2019 (23261)
2018 (17474)
2017 (18769)
2016 (17925)
2015 (24272)
2014 (21680)
2013 (18139)
2012 (20221)
2011 (20441)
2010 (20333)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17887)
Australia (2097)
California (11907)
Canada (3127)
China (518)
Colorado (481)
Connecticut (407)
Delaware (207)
Europe (24644)
Florida (1782)
Georgia (375)
Hawaii (3)
Idaho (46)
Illinois (696)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7829)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2611)
New Mexico (12)
New York (2812)
North Carolina (1268)
North Dakota (4)
Northern California (5962)
Ohio (276)
Oklahoma (14)
Oregon (18)
Pennsylvania (2244)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4942)
Tennessee (119)
Texas (1925)
United States (38687)
Utah (358)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (921)
West Virginia (1)
Wisconsin (73)
484,529 Results for "agenus inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
July 29, 2026
·
3 min read
Press Releases
Agenus Announces Virtual 2026 Annual Shareholders Meeting
June 3, 2026
·
1 min read
Cell therapy
Agenus cancer cocktail records 0% response rate, missing midstage goal
An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.
April 20, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
August 6, 2026
·
13 min read
Press Releases
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
July 19, 2026
·
5 min read
Press Releases
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 5, 2026
·
3 min read
Press Releases
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
July 13, 2026
·
15 min read
Press Releases
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 21, 2026
·
7 min read
Press Releases
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
June 25, 2026
·
4 min read
Press Releases
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
July 6, 2026
·
9 min read
1 of 48,453
Next
